Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells

Circulation Research

Volumn 85, Issue 2, 1999, Pages 208-217

  Banfi, Cristina ^b   Mussoni, Luciana ^b   Risé, Patrizia ^b   Cattaneo, Maria Grazia ^b   Vicentini, Lucia ^b   Battaini, Fiorenzo ^b   Galli, Claudio ^b   Tremoli, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

Fibrinolysis; Hepatoma cell line; Plasminogen activator inhibitor type 1; Signaling; VLDL

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 3,4,5 TRIMETHOXYBENZOIC ACID 8 (DIETHYLAMINO)OCTYL ESTER; ARACHIDONIC ACID; CALCIUM ION; MEPACRINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE D; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR DISEASE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBRINOLYSIS; HUMAN; HUMAN CELL; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033597961     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.85.2.208     Document Type: Article

References (66)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
2. Fuller J, Shimpley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: The Whitehall Study. Lancet. 1980;i:1373-1376.
3. Frayn KN. Insulin resistance and lipid metabolism. Curr Opin Lipidol. 1993;4:197-204.
4. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis. Baillieres Clin Haematol. 1995;8:345-363.
5. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
6. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
7. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab. 1987;13: 331-336.
8. Metha J, Metha P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol. 1987;9: 263-268.
9. Mussoni L, Mannucci L, Sinon M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1992;12:19-27.
10. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990; 10:1067-1073.
11. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20-26.
12. Sironi L, Mussoni L, Prati L, Baldassarre D, Camera M, Banfi C, Tremoli E. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol. 1996;16:89-96.
13. Santell L, Levin EG. Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. J Biol Chem. 1988; 263:16802-16808.
14. Kooistra T, Bosma PJ, Toet K, Cohen LH, Griffioen M, van den Berg E, le Clercq L, van Hinsbergh VW. Role of protein kinase C and cyclic adenosine monophosphate in the regulation of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and platelet-derived growth factor mRNA levels in human endothelial cells: possible involvement of proto-oncogenes c-jun and c-fos. Arterioscler Thromb. 1991;11: 1042-1052.
15. Bergonzelli GE, Kruithof EK, Medcalf RL. Transcriptional antagonism of phorbol ester-mediated induction of plasminogen activator inhibitor types 1 and 2 by cyclic adenosine 3′,5′-monophosphate. Endocrinology. 1992; 131:1467-1472.
16. Slivka SR, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor synthesis by protein kinase C and cAMP in bovine aortic endothelial cells. Biochim Biophys Acta. 1991;1094:317-322.
17. Tranque P, Robbins R, Naftolin F, Andrade-Gordon P. Regulation of plasminogen activators and type-1 plasminogen activator inhibitor by cyclic AMP and phorbol ester in rat astrocytes. Glia. 1992;6:163-171.
18. Le Magueresse-Battistoni B, Pernod G, Kolodie L, Morera AM, Benahmed M. Tumor necrosis factor-alpha regulates plasminogen activator inhibitor-1 in rat testicular peritubular cells. Endocrinology. 1997; 138:1097-1105.
19. Halstead J, Kemp K, Ignotz RA. Evidence for involvement of phosphatidylcholine-phospholipase C and protein kinase C in transforming growth factor-beta signaling. J Biol Chem. 1995;270: 13600-13603.
20. Rydzewski B, Zelezna B, Tang W, Sumners C, Raizada MK. Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain. Endocrinology. 1992;130:1255-1262.
21. van Hinsbergh VW, Vermeer M, Koolwijk P, Grimbergen J, Kooistra T. Genistein reduces tumor necrosis factor alpha-induced plasminogen activator inhibitor-1 transcription but not urokinase expression in human endothelial cells. Blood. 1994;84:2984-2991.
22. Peiretti F, Fossat C, Anfosso F, Alessi MC, Henry M, Juhan-Vague I, Nalbone G. Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. Blood. 1996;87:162-173.
23. Scott-Burden T, Resink TJ, Hahn AW, Baur U, Box RJ, Buhler FR. Induction of growth-related metabolism in human vascular smooth muscle cells by low density lipoprotein. J Biol Chem. 1989;264: 12582-12589.
24. Deeg MA, Bowen RF, Oram JF, Bierman EL. High density lipoproteins stimulate mitogen-activated protein kinases in human skin fibroblasts. Arterioscler Thromb Vasc Biol. 1997;17:1667-1674.
25. Kusuhara M, Chait A, Cader A, Berk BC. Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 1997;17:141-148.
26. Chautan M, Latron Y, Anfosso F, Alessi MC, Lafont H, Juhan-Vague I, Nalbone G. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J Lipid Res. 1993;34:101-110.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
28. Pascale A, Fortino I, Govoni S, Trabucchi M, Wetsel WC, Battaini F. Functional impairment in protein kinase C by RACK1 (receptor for activated C kinase 1) deficiency in aged rat brain cortex. J Neurochem. 1996;67:2471-2477.
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
30. Risé P, Colombo C, Galli C. Effects of simvastatin on the metabolism of polyunsaturated fatty acids and on glycerolipid, cholesterol, and de novo lipid synthesis in THP-1 cells. J Lipid Res. 1997;38:1299-1307.
31. Folch J, Lees M, Sloane-Stanley GHS. A simple method for isolation of total lipids from animal tissues. J Biol Chem. 1956;226:497-509.
32. Martinson EA, Trilivas I, Brown JH. Rapid protein kinase C-dependent activation of phospholipase D leads to delayed 1,2-diglyceride accumulation. J Biol Chem. 1990;265:22282-22287.
33. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
34. Seger R, Seger D, Reszka AA, Munar ES, Eldar-Finkelman H, Dobrowolska G, Jensen AM, Campbell JS, Fischer EH, Krebs EG. Over-expression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells: evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. J Biol Chem. 1994;269:25699-25709.
35. Tatrai A, Lee SK, Stern PH. U-73122, a phospholipase C antagonist, inhibits effects of endothelin-1 and parathyroid hormone on signal transduction in UMR-106 osteoblastic cells. Biochim Biophys Acta. 1994; 1224:575-582.
36. Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kronke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell. 1992;71: 765-776.
37. 2+ requirement for optimal lipid peroxidation of low density lipoprotein by activated human monocytes. J Clin Invest. 1993;91:1499-1506.
38. Cobb MH, Boulton TG, Robbins DJ. Extracellular signal-regulated kinases: ERKs in progress. Cell Regul. 1991;2:965-978.
39. Thomas G. MAP kinase by any other name smells just as sweet. Cell. 1992;68:3-6.
40. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995;92:7686-7689.
41. Dawson RM. The formation of phosphatidylglycerol and other phospholipids by the transferase activity of phospholipase D. Biochem J. 1967; 102:205-210.
42. Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, Fukui Y, Nonomura Y, Matsuda Y. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem. 1993;268:25846-25856.
43. Voyno-Yasenetskaya TA, Dobbs LG, Erickson SK, Hamilton RL. Low density lipoprotein- and high density lipoprotein-mediated signal transduction and exocytosis in alveolar type II cells. Proc Natl Acad Sci U S A. 1993;90:4256-4260.
44. Macarthur H, Hecker M, Busse R, Vane JR. Selective inhibition of agonist-induced but not shear stress-dependent release of endothelial autacoids by thapsigargin. Br J Pharmacol. 1993;108:100-105.
45. Farrar WL, Thomas TP, Anderson WB. Altered cytosol/membrane enzyme redistribution on interleukin-3 activation of protein kinase C. Nature. 1985;315:235-237.
46. Ducher L, Croquet F, Gil S, Davy J, Feger J, Brehier A. Differential expression of five protein kinase C isoenzymes in FAO and HepG2 hepatoma cell lines compared with normal rat hepatocytes. Biochim Biophys Res Commun. 1995;217:546-553.
47. Arts J, Grimbergen J, Bosma PJ, Rahmsdorf HJ, Kooistra T. Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMA-stimulated plasminogen-activator inhibitor-1 gene expression in HepG2. Eur J Biochem. 1996;241:393-402.
48. Dennis EA. Phospholipases. In The Enzymes. 3rd ed. New York, NY: Academic Press, 1983;16:307-353.
49. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993;72:269-278.
50. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995;270:14843-14846.
51. Adams PD, Parker PJ. TPA-induced activation of MAP kinase. FEBS Lett. 1991;290:77-82.
52. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A. 1993;90:5889-5892.
53. Blumer KJ, Johnson GL. Diversity in function and regulation of MAP kinase pathways. Trends Biochem Sci. 1994;19:236-240.
54. Post GR, Brown JH. G protein-coupled receptors and signaling pathways regulating growth responses. FASEB J. 1996;10:741-749.
55. Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science. 1993;260:315-319.
56. Leevers SJ, Marshall CJ. Activation of extracellular signal-regulated kinase, ERK2, by p21 ras oncoprotein. EMBO J. 1992;11:569-574.
57. Lee H, Ghose-Dastidar J, Winawer S, Friedman E. Signal transduction through extracellular signal-regulated kinase-like pp57 blocked in differentiated cells having low protein kinase cβ activity. J Biol Chem. 1993; 268:5255-5263.
58. Havel RJ, Kane JP. Lipoprotein and lipid metabolism disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Bases of Inherited Disease. New York, NY: McGraw-Hill; 1989:1129-1302.
59. Javitt NB. HepG2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J. 1990;4:161-168.
60. Webb JC, Patel DD, Jones MD, Knight BL, Soutar AK. Characterization and tissue-specific expression of the human "very low density lipoprotein (VLDL) receptor" mRNA. Hum Mol Genet. 1994;3: 531-537.
61. Allen S, Khan S, Al-Mohanna F, Batten P, Yacoub M. Native low density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J Clin Invest. 1998;101:1064-1075.
62. Pian MS, Dobbs LG. Lipoprotein-stimulated surfactant secretion in alveolar type II cells: mediation by heterotrimeric G proteins. Am J Physiol. 1997;273:L634-L639.
63. Banfi C, Risé P, Mussoni L, Galli C, Tremoli E. Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. J Lipid Res. 1997;38:860-869.
64. Nilsson L, Banfi C, Diczfalusky U, Tremoli E, Hamsten A, Eriksson P. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18: 1679-1685.
65. Rao GN, Baas AS, Glasgow WC, Eling TE, Runge MS, Alexander RW. Activation of mitogen-activated protein kinases by arachidonic acid and its metabolites in vascular smooth muscle cells. J Biol Chem. 1994;269: 32586-32591.
66. Rao GN, Alexander RW, Runge MS. Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest. 1995;96: 842-847.